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Background: The aim of this trial was to investigate the elimination of paclitaxel from the arterial wall following a single short lasting 
administration with a coated balloon.
Methods: Paclitaxel coated balloon catheters without or with premounted stents were inflated in coronary arteries of either young domestic pigs 
or adult minipigs. The paclitaxel content of plasma samples, treated arterial segments and residual hearts was measured up to 180 days using high 
performance liquid chromatography/ UV- detection or mass spectrometry. Angiograms were evaluated for lumen narrowing.
Results: Paclitaxel concentration in plasma remained below 10ng/ml. In arteries of domestic pigs (minipigs) treated with balloons with 
premounted stents 10% (20%) of dose was initially detected. Within 7d the paclitaxel content decreased to 3.5%. Until 6 months it fell with a half-
life of ca. 1.9 months to 0.4%. After 3 months the concentration in the arterial wall was 17±11 μM. Without stent the drug transfer to the vessel wall 
was somewhat lower and the elimination faster. Immediately after treatment up to about 25% of dose were detected in the residual whole heart. The 
paclitaxel content dropped with a half-life of ca. 45 days to 1.5% of dose (0.3μM) within 6 months.
Conclusion: After a single local administration with coated balloons paclitaxel stays long enough in the vessel wall of pigs to explain persistent 
inhibition of neointimal proliferation. Pharmacokinetics of paclitaxel does, however, not exclude other reasons for sustained efficacy such as early 
blocking of processes initiating excessive and prolonged neointimal proliferation. 
